Novo Nordisk A/S $NVO Shares Sold by Merit Financial Group LLC

Merit Financial Group LLC reduced its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 66.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 20,195 shares of the company’s stock after selling 40,415 shares during the period. Merit Financial Group LLC’s holdings in Novo Nordisk A/S were worth $1,121,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. NewSquare Capital LLC raised its stake in Novo Nordisk A/S by 174.1% during the second quarter. NewSquare Capital LLC now owns 444 shares of the company’s stock worth $31,000 after purchasing an additional 282 shares during the period. Mid American Wealth Advisory Group Inc. acquired a new stake in shares of Novo Nordisk A/S during the 2nd quarter worth $37,000. State of Wyoming purchased a new position in shares of Novo Nordisk A/S in the 1st quarter worth $38,000. Maseco LLP acquired a new position in Novo Nordisk A/S in the second quarter valued at $39,000. Finally, Copeland Capital Management LLC grew its position in Novo Nordisk A/S by 47.3% during the second quarter. Copeland Capital Management LLC now owns 579 shares of the company’s stock valued at $40,000 after acquiring an additional 186 shares during the period. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Novo Nordisk A/S Stock Up 5.4%

Shares of NYSE:NVO opened at $55.21 on Tuesday. The company has a market capitalization of $246.49 billion, a price-to-earnings ratio of 16.05 and a beta of 0.66. The company has a 50 day moving average of $49.13 and a two-hundred day moving average of $55.57. Novo Nordisk A/S has a 52-week low of $43.08 and a 52-week high of $93.80. The company has a quick ratio of 0.57, a current ratio of 0.78 and a debt-to-equity ratio of 0.52.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Wednesday, November 5th. The company reported $1.02 earnings per share for the quarter, beating the consensus estimate of $0.77 by $0.25. Novo Nordisk A/S had a net margin of 32.76% and a return on equity of 73.50%. The business had revenue of $11.79 billion during the quarter, compared to the consensus estimate of $11.98 billion. As a group, analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Wegovy pill is now broadly available across the U.S., giving patients a once‑daily oral GLP‑1 alternative to injectables and expanding addressable market and patient choice. This supports upside to near‑term retail adoption and long‑term obesity franchise growth. WSJ: Wegovy Pill Now Broadly Available
• Positive Sentiment: Novo is offering self‑pay pricing starting at $149/month for the Wegovy pill (1.5 mg starter), positioning it as one of the cheaper cash options to drive uptake among uninsured or self‑pay patients and speed scale. Lower cash price could translate to faster patient volume and fill rates. Reuters: Wegovy Pill $149/month
• Positive Sentiment: Distribution is extensive: Wegovy pills are reported available at 70,000+ U.S. pharmacies, through telehealth partners and NovoCare, increasing access and lowering friction to patient starts — a catalyst for faster revenue ramp if persistence is solid. PR Newswire: Broad Availability
• Positive Sentiment: Market reaction: coverage notes rival stocks (e.g., Lilly, Viking) moving lower on the pill’s arrival, implying competitive share gain for Novo and possible sector re‑rating tailwinds. MSN: Competitors’ Stocks Down
• Neutral Sentiment: Regulatory path outside the U.S.: the U.K. regulator is reviewing Novo’s Wegovy pill application and may decide by year‑end — a potential future revenue catalyst but uncertain timing. Reuters: UK Review
• Negative Sentiment: Corporate/communications risk: Reuters reports Novo’s U.S. head of public affairs has left the company, which could complicate stakeholder engagement as Novo pushes to revive U.S. momentum; investors should watch for execution and messaging gaps. Reuters: Public Affairs Head Leaves

Analysts Set New Price Targets

A number of equities analysts have recently commented on NVO shares. BMO Capital Markets restated a “market perform” rating on shares of Novo Nordisk A/S in a report on Tuesday, December 23rd. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from a “market perform” rating to an “outperform” rating in a report on Tuesday, September 9th. Argus reaffirmed a “hold” rating on shares of Novo Nordisk A/S in a research report on Monday, December 8th. Zacks Research lowered shares of Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a research report on Wednesday, December 3rd. Finally, Morgan Stanley reissued an “underweight” rating and issued a $42.00 target price on shares of Novo Nordisk A/S in a research note on Wednesday, December 3rd. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, eleven have assigned a Hold rating and four have given a Sell rating to the company’s stock. According to data from MarketBeat, Novo Nordisk A/S has an average rating of “Hold” and an average price target of $53.33.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.